Financial Performance - The company's revenue for Q1 2024 was ¥108,322,506.68, a decrease of 80.34% compared to ¥551,007,175.69 in the same period last year[5] - Net profit attributable to shareholders was ¥2,068,381.83, down 99.32% from ¥304,306,229.57 year-on-year[5] - Basic and diluted earnings per share fell to ¥0.02, a decline of 99.17% compared to ¥2.42 in the same period last year[5] - Total operating revenue for Q1 2024 was CNY 108.32 million, a significant decrease of 80.4% compared to CNY 551.01 million in the same period last year[21] - Net profit for Q1 2024 was CNY 2.07 million, a decline of 99.3% compared to CNY 304.31 million in Q1 2023[22] - Earnings per share for Q1 2024 were CNY 0.02, a decrease from CNY 2.42 in the same period last year[23] Cash Flow - The net cash flow from operating activities decreased by 50.83% to ¥52,145,490.57 from ¥106,060,159.69 in the previous year[5] - Cash inflow from operating activities was CNY 137.06 million, down 65.9% from CNY 402.24 million in the same quarter last year[25] - The net cash flow from operating activities for Q1 2024 was CNY 52,145,490.57, a decrease from CNY 106,060,159.69 in Q1 2023, reflecting a decline of approximately 51%[26] - The company reported cash outflows from operating activities totaling CNY 84,910,887.82 in Q1 2024, compared to CNY 296,183,127.82 in Q1 2023, showing a reduction of approximately 71%[26] - The company experienced a net increase in cash and cash equivalents of CNY 158,434,972.87 in Q1 2024, contrasting with a decrease of CNY 928,468.05 in Q1 2023[26] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥1,818,868,459.23, a slight decrease of 1.09% from ¥1,838,994,561.98 at the end of the previous year[5] - Total current assets decreased to ¥785,429,083.52 from ¥822,169,778.54, a decline of 4.5%[18] - Total liabilities decreased to CNY 213.53 million, down 9.4% from CNY 235.72 million in the previous quarter[20] - The company's equity attributable to shareholders increased to CNY 1.61 billion, up from CNY 1.60 billion in the previous quarter[20] Research and Development - Research and development expenses increased by 50.92% to ¥8,246,051.34 from ¥5,463,699.61 in the same period last year[8] - Research and development expenses increased to CNY 8.25 million, up 50.5% from CNY 5.46 million in the previous year[21] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 24,814[11] - The largest shareholder, Yang Xining, holds 27.23% of shares, totaling 34,455,650 shares[11] - The number of shares held by the top 10 shareholders includes SHENGLIN HOLDING CO. LTD. with 13.67% and Cai Yuying with 4.19%[11] - The total number of shares held by the top 10 unrestricted shareholders is 17,297,407 shares[12] - The company has a total of 47,473,794 restricted shares at the end of the reporting period[15] - The company plans to release 25% of the restricted shares held by executives annually during their tenure[15] Other Financial Metrics - The company reported a significant decrease in operating income primarily due to reduced sales of raw materials[8] - The company experienced a 63.29% decrease in trading financial assets, dropping to ¥70,000,000.00 from ¥190,704,998.30[8] - The company reported a 345.84% increase in fair value changes in financial assets, resulting in a loss of ¥704,998.30 compared to a loss of ¥158,127.86 in the previous year[8] - Total operating costs for Q1 2024 were CNY 111.60 million, down 23.1% from CNY 145.29 million year-over-year[21] - Deferred income tax liabilities were CNY 5.86 million, slightly down from CNY 6.04 million in the previous quarter[20] Audit and Accounting - The first quarter report was not audited, indicating that the figures presented are preliminary and subject to change[28] - The company did not execute any new accounting standards adjustments for the first quarter of 2024[28]
拓新药业(301089) - 2024 Q1 - 季度财报